2. Signaling Pathways
  3. Immunology/Inflammation
  4. Kallikrein

Kallikrein

KLK; Kallikrein-related peptidase

Kallikrein is a serine protease that plays a crucial role in the kallikrein-kinin system. Plasma kallikrein, specifically expressed in hepatocytes, acts on high molecular weight kininogen to release bradykinin, which is involved in regulating vascular tone, inflammatory response, and endogenous blood coagulation and fibrinolysis. Tissue kallikrein, widely distributed in various tissues such as the lung, kidney, and brain, acts on low molecular weight kininogen to produce kinin, participating in processes like blood pressure regulation, electrolyte balance, and neuronal protection. Additionally, kallikrein can bind to LDLR, promoting its lysosomal degradation, and interact with ASICs to affect neuronal function in the central nervous system. Dysregulation of kallikrein activity is associated with various diseases including heart disease, kidney disease, and cancer[1][2].

Kallikrein Isoform Specific Products:

Kallikrein Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139787A
    Donidalorsen sodium
    		Inhibitor
    Donidalorsen (sodium) is an antisense oligonucleotide designed to reduce the production of prekallikrein (PKK). PKK plays an important role in the activation of inflammatory mediators associated with acute attacks of Hereditary angioedema (HAE).
    Donidalorsen sodium
  • HY-143476
    Plasma kallikrein-IN-2
    		Inhibitor
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
    Plasma kallikrein-IN-2
  • HY-150052
    Plasma kallikrein-IN-3
    		Inhibitor
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
    Plasma kallikrein-IN-3
  • HY-167924
    Ono 3307 free base
    Ono 3307 Free base is a novel synthetic protease inhibitor that exhibits protective effects against acute pancreatitis by preventing hyperamylasemia and pancreatic edema. Ono 3307 Free base also inhibits the redistribution of lysosomal enzymes in acinar cells and mitigates lactic dehydrogenase discharge. Ono 3307 Free base effectively reduces cathepsin B leakage from lysosomes in a dose-dependent manner. Ono 3307 Free base is able to target trypsin (Ki=48 nM), thrombin (Ki=0.18 μM), plasma kallikrein (Ki=0.29 μM), plasmin (Ki=0.31 μM), pancreatic kallikrein (Ki=3.6 μM), and chymotrypsin (Ki=47 μM).
    Ono 3307 free base
  • HY-19101
    ONO-3307
    		Inhibitor
    ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases.
    ONO-3307
  • HY-163464
    Plasma kallikrein-IN-5
    		Inhibitor
    Plasma kallikrein-IN-5 (Compound 20) is a potent covalent inhibitor of plasma potassium kinin peptide (Pka) with IC50 values of 66 nM and 70 pM at 1 minute and 24 hours, respectively. Plasma kallikrein-IN-5 can be used IN the study of hereditary angioedema (HAE).
    Plasma kallikrein-IN-5
  • HY-P5027
    Cbz-Lys-Arg-pNA
    		Substrate
    Cbz-Lys-Arg-pNA is a peptide substrate containing pNA as the chromogenic group. Cbz-Lys-Arg-pNA is widely used in enzymatic analysis, including thrombin, plasmin, factor Xa and Kallikrein.
    Cbz-Lys-Arg-pNA
  • HY-P0237
    KKI-5
    KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion.
    KKI-5
Cat. No. Product Name / Synonyms Application Reactivity
Kallikrein Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.